Who Owns the Ocean’s Genes? Tension on the High Seas
By Olive Heffernan,
Scientific American
| 09. 12. 2022
Tavis Beck on Unsplash
After nearly two weeks of recent United Nations negotiations in New York City, countries from around the world failed to finalize an ambitious treaty that would create enormous marine protected areas and enforce stricter rules for industry on the high seas—the two thirds of the ocean beyond any country’s exclusive ocean territory. The deal faltered in the final hours, mainly over an issue that has long dogged international ocean talks: how to share profits from commercializing the high seas’ genetic resources.
Ocean organisms, both plants and animals, form the basis of numerous successful drugs, including remdesivir, the first treatment approved for COVID, and Halaven, a blockbuster anticancer drug derived from a Japanese sea sponge that has annual sales of more than $300 million. Genetic material from high seas organisms and the digital data from sequencing their genomes could be used to develop new products potentially worth billions of dollars. But who owns these resources, which theoretically belong to the entire world, and who gets to profit from their use? The details of where U.N. negotiators...
Related Articles
By Arthur Lazarus, MedPage Today | 01.23.2026
A growing body of contemporary research and reporting exposes how old ideas can find new life when repurposed within modern systems of medicine, technology, and public policy. Over the last decade, several trends have converged:
- The rise of polygenic scoring...
By Stephanie Pappas, LiveScience | 01.15.2026
Genetic variants believed to cause blindness in nearly everyone who carries them actually lead to vision loss less than 30% of the time, new research finds.
The study challenges the concept of Mendelian diseases, or diseases and disorders attributed to...
By David Cox, Wired | 01.05.2026
As he addressed an audience of virologists from China, Australia, and Singapore at October’s Pandemic Research Alliance Symposium, Wei Zhao introduced an eye-catching idea.
The gene-editing technology Crispr is best known for delivering groundbreaking new therapies for rare diseases, tweaking...
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...